Clarity Pharmaceuticals获FDA突破性疗法认定，用于前列腺癌铜基诊疗一体化药物
· smallcaps.com.au
Clarity Pharmaceuticals的前列腺癌PET显像剂64Cu-SAR-bisPSMA获得美国FDA突破性疗法认定，这是其铜基诊疗一体化项目的一个重要里程碑。
The US Food and Drug Adminstration has granted Clarity Pharmaceuticals (ASX: CU6) breakthrough therapy designation for 64Cu-SAR-bisPSMA used in positron emissio...